Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial.

Lampa J, Nordström D, van Vollenhoven R, Lund Hetland M, Haavardsholm EA, Østergaard M, Rudin A, Heiberg MS, Nurmohamed M, Gudbjornsson B, Lend K, Hørslev-Petersen K, Sokka-Isler T, Gröndal G, Krabbe S, Lindqvist J, Gjertsson I, Glinatsi D, Kapetanovic M, Gentline C, Aga AB, Relas H, Lorenzen T, Cagnotto G, Back J, Hendricks O, Dijkshoorn B, Öberg K, Ljoså MK, Brodin E, Lindegaard HM, Söderbergh A, Rizk M, Kastbom A, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Laurberg TB, Bakland G, Olsen IC, Sexton J, Uhlig T, NORD-STAR study group

Open source

DOI
10.1016/s2665-9913(26)00007-x
Published
2026 Apr
Container
The Lancet. Rheumatology
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s2665-9913-26-00007-x,
  title = {Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial.},
  author = {Lampa J and Nordström D and van Vollenhoven R and Lund Hetland M and Haavardsholm EA and Østergaard M and Rudin A and Heiberg MS and Nurmohamed M and Gudbjornsson B and Lend K and Hørslev-Petersen K and Sokka-Isler T and Gröndal G and Krabbe S and Lindqvist J and Gjertsson I and Glinatsi D and Kapetanovic M and Gentline C and Aga AB and Relas H and Lorenzen T and Cagnotto G and Back J and Hendricks O and Dijkshoorn B and Öberg K and Ljoså MK and Brodin E and Lindegaard HM and Söderbergh A and Rizk M and Kastbom A and Larsson P and Uhrenholt L and Just SA and Stevens DJ and Laurberg TB and Bakland G and Olsen IC and Sexton J and Uhlig T and NORD-STAR study group},
  year = {2026},
  journal = {The Lancet. Rheumatology},
  doi = {10.1016/s2665-9913(26)00007-x},
  url = {https://doi.org/10.1016/s2665-9913(26)00007-x}
}

RIS

TY  - JOUR
TI  - Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial.
AU  - Lampa J
AU  - Nordström D
AU  - van Vollenhoven R
AU  - Lund Hetland M
AU  - Haavardsholm EA
AU  - Østergaard M
AU  - Rudin A
AU  - Heiberg MS
AU  - Nurmohamed M
AU  - Gudbjornsson B
AU  - Lend K
AU  - Hørslev-Petersen K
AU  - Sokka-Isler T
AU  - Gröndal G
AU  - Krabbe S
AU  - Lindqvist J
AU  - Gjertsson I
AU  - Glinatsi D
AU  - Kapetanovic M
AU  - Gentline C
AU  - Aga AB
AU  - Relas H
AU  - Lorenzen T
AU  - Cagnotto G
AU  - Back J
AU  - Hendricks O
AU  - Dijkshoorn B
AU  - Öberg K
AU  - Ljoså MK
AU  - Brodin E
AU  - Lindegaard HM
AU  - Söderbergh A
AU  - Rizk M
AU  - Kastbom A
AU  - Larsson P
AU  - Uhrenholt L
AU  - Just SA
AU  - Stevens DJ
AU  - Laurberg TB
AU  - Bakland G
AU  - Olsen IC
AU  - Sexton J
AU  - Uhlig T
AU  - NORD-STAR study group
PY  - 2026
JO  - The Lancet. Rheumatology
DO  - 10.1016/s2665-9913(26)00007-x
UR  - https://doi.org/10.1016/s2665-9913(26)00007-x
ER  -

APA

J, L., D, N., R, V. V., M, L. H., EA, H., M, Ø., A, R., MS, H., M, N., B, G., K, L., K, H., T, S., G, G., S, K., J, L., I, G., D, G., M, K., C, G., AB, A., H, R., T, L., G, C., J, B., O, H., B, D., K, Ö., MK, L., E, B., HM, L., A, S., M, R., A, K., P, L., L, U., SA, J., DJ, S., TB, L., G, B., IC, O., J, S., T, U., & group, N. S. (2026). Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial.. The Lancet. Rheumatology. https://doi.org/10.1016/s2665-9913(26)00007-x

Source records